rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1999-8-5
|
pubmed:abstractText |
In vitro data demonstrated a dose-response relationship for doxorubicin in ovarian cancer (OC) cell lines. However, this dose-response question for doxorubicin was never carefully addressed in OC patients. These data and the more favorable toxicity profile of the anthracycline analogue epirubicin prompted us to study high-dose epirubicin (HDE) in relapsed OC patients.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0030-2414
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
57
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10394119-Adult,
pubmed-meshheading:10394119-Antibiotics, Antineoplastic,
pubmed-meshheading:10394119-Antineoplastic Agents,
pubmed-meshheading:10394119-Cisplatin,
pubmed-meshheading:10394119-Drug Administration Schedule,
pubmed-meshheading:10394119-Epirubicin,
pubmed-meshheading:10394119-Female,
pubmed-meshheading:10394119-Humans,
pubmed-meshheading:10394119-Leukopenia,
pubmed-meshheading:10394119-Middle Aged,
pubmed-meshheading:10394119-Ovarian Neoplasms,
pubmed-meshheading:10394119-Thrombocytopenia,
pubmed-meshheading:10394119-Treatment Outcome
|
pubmed:year |
1999
|
pubmed:articleTitle |
Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma.
|
pubmed:affiliation |
University Hospital 'Vrije Universiteit', Amsterdam, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|